Jade Biosciences, Inc. (JBIO)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$15.07

+0.97 (+6.88%)

Market Cap: $896.72M

Last updated: Nov 06, 2026 at 4:15 PM ET

Earnings

Performance (10Y)

Beat Rate

5%(1/21)

Avg Surprise

-1654.71%

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-0.79

Range$-0.79 - $-0.79

1 analysts

EPS RevisionsNo revisions (7d)

30d

EPS Estimate DriftChange to current

90d ago$-0.57-39.1%

60d ago$-0.790.0%

30d ago$-0.790.0%

7d ago$-0.790.0%

Current$-0.79

Revenue Consensus

Range$0 - $0

8 analysts

Period ending Dec 31, 2026

EPS Consensus$-1.13

Range$-1.13 - $-1.13

1 analysts

Revenue Consensus

Range$0 - $0

8 analysts

Last 12 of 22 reported quarters and 2 upcoming estimates

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-1.13	$-1.13 - $-1.13	-	-	1	-	-
Sep 30, 2026Sep 26EST	-	$-0.79	$-0.79 - $-0.79	-	-	1	0 1 30d	-
Jun 30, 2026Jun 26 Reported Aug 10, 2026Reported Aug 10	$-0.76	$-0.66	$-0.66 - $-0.66	-15.15%	Miss	1	No revisions (30d)	+11.6%
Mar 31, 2026Mar 26 Reported May 7, 2026Reported May 7	$-0.57	$-0.48	$-0.57 - $-0.38	-18.75%	Miss	8	3 2 30d	+95.3%
Dec 31, 2025Dec 25 Reported Mar 6, 2026Reported Mar 6	$N/A	$-0.47	$-0.65 - $-0.35	N/A	Beat	7	0 1 30d	-
Sep 30, 2025Sep 25 Reported Nov 13, 2025Reported Nov 13	$-0.48	$-0.67	$-0.67 - $-0.67	+28.36%	Beat	0	No revisions (30d)	+97.6%
Jun 30, 2025Jun 25 Reported Aug 13, 2025Reported Aug 13	$-0.86	$-0.48	$-0.48 - $-0.48	-79.17%	Miss	0	No revisions (30d)	+97.1%
Mar 31, 2025Mar 25 Reported Apr 25, 2025Reported Apr 25	$-12.10	$-2.05	-	-490.24%	Miss	-	-	-1357.8%
Dec 31, 2024Dec 24 Reported Mar 27, 2025Reported Mar 27	$-6.61	$-0.40	-	-1542.24%	Miss	-	-	+74.5%
Sep 30, 2024Sep 24 Reported Nov 11, 2024Reported Nov 11	$-19.60	$-0.58	-	-3274.66%	Miss	-	-	-2660.6%
Jun 30, 2024Jun 24 Reported Aug 12, 2024Reported Aug 12	$-30.10	$-0.85	-	-3441.18%	Miss	-	-	-3860.5%
Mar 31, 2024Mar 24 Reported May 13, 2024Reported May 13	$-0.83	$-0.76	-	-9.21%	Miss	-	-	-23.9%
Dec 31, 2023Dec 23 Reported Mar 25, 2024Reported Mar 25	$-25.90	$-0.74	-	-3400.00%	Miss	-	-	-21.3%
Sep 30, 2023Sep 23 Reported Nov 13, 2023Reported Nov 13	$-0.71	$-0.69	-	-2.90%	Miss	-	-	-26.8%

Dividends

Last ex-dividend: Apr 29, 2025

Dividend Metrics

Forward Yield0.00%

Forward Annual Dividend$0.00

Key Metrics

Valuation
P/E Ratio	N/A	EV/EBITDA	N/A
Price/FCF	N/A	FCF Yield	N/A
Profitability
Profit Margin	0.00%	Operating Margin	0.00%
ROE	-89.20%	ROIC	N/A
Financial Health
Debt/Equity	0.00x	Interest Coverage	N/A
Current Ratio	14.93x	Quick Ratio	14.93x
Trading Statistics
Beta	N/A	Avg Volume	940.85K
52-Week High	$28.00	52-Week Low	$8.82

Technical Indicators Dashboard

Moving Averages

SMA 10$14.48

SMA 20$14.31

SMA 50$15.80

SMA 200$18.22

EMA 10$14.53

EMA 20$14.57

EMA 50$15.80

EMA 200$16.99

MACD

Line: -0.25Signal: -0.43Hist: 0.19

ADX

ADX: 27.1+DI: 13.8-DI: 22.8

Aroon & PSAR

Aroon Up56.0

Aroon Down32.0

PSAR$15.29

Bollinger Bands

Upper Band$15.44

Lower Band$13.19

%B Position1574%(Upper)

Band Width0.84

RSI (14-Day)

Neutral

52.5

Momentum Oscillators

Stoch %K64.4

Stoch %D62.1

Williams %R-19.6

ROC (10d)3.3%

Momentum0.48

CCI (20d)46.7

MFI (14d)49.2

Volatility Measures

ATR (14d)$0.90(6.0%)

StdDev (20d)0.56

Hist Vol55.9%(High)

Volume Flow

VWAP$14.61

OBV-1.6M

AD Line-8.0M

CMF (20d)-0.086

Volume Metrics

Avg Vol (20d)914.8K

Vol Ratio0.7x

VWMA (20d)$14.24

Pivot Points

R3$15.70

R2$15.36

R1$14.73

Pivot Point$14.39

S1$13.77

S2$13.43

S3$12.80

Advanced Oscillators

TSI-9.57

Ultimate Osc53.6

KST-37.00

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	N/A	$0
Cost of Revenue	$0	$0	$9,000	$0	$0	$0	$8,000	$0	$0	$0	$28,000	$0
Gross Profit	$0	$0	$-9,000	$0	$0	$0	$-8,000	$0	$0	$0	$-28,000	$0

Operating Expenses	$58.92M	$43.45M	$54.98M	$27.40M	$27.78M	$23.38M	$6.40M	$15.55M	$26.16M	$24.62M	$22.07M	$21.37M
R&D	$50.06M	$36.05M	$48.56M	$22.01M	$22.55M	$20.02M	$1.53M	$13.66M	$21.25M	$20.08M	$17.81M	$16.88M
SG&A	$8.85M	$7.39M	$6.41M	$5.39M	$5.23M	$3.36M	$4.87M	$1.90M	$4.92M	$4.54M	$4.25M	$4.48M
Operating Income	$-58,916,000	$-43,445,000	$-54,976,000	$-27,401,000	$-27,778,000	$-23,384,000	$-6,403,000	$-15,555,000	$-26,165,000	$-24,618,000	$-22,066,000	$-21,368,000

Interest Income	$3.23M	$3.10M	$2.83M	$2.25M	$1.83M	$615,000	$1.03M	$388,000	$1.40M	$1.44M	$1.71M	$1.80M
Interest Expense	$0	$0	$12.61M	$0	$4.36M	$14.79M	$0	$1.31M	$0	$0	$0	$0
Income Before Tax	$-55,750,000	$-40,352,000	$-67,588,000	$-25,112,000	$-32,134,000	$-38,169,000	$-5,375,000	$-16,867,000	$-24,775,000	$-23,186,000	$-20,357,000	$-19,563,000
Income Tax Expense	$15,000	$16,000	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0

Net Income	$-55,765,000	$-40,368,000	$-67,583,000	$-25,175,000	$-32,134,000	$-38,169,000	$-5,430,000	$-16,867,000	$-24,775,000	$-23,186,000	$-20,413,000	$-19,563,000

EBITDA	$-59,327,000	$-43,929,000	$-55,577,000	$-27,354,000	$-33,957,000	$-38,784,000	$-6,731,000	$-16,908,000	$-26,835,000	$-25,349,000	$-22,977,000	$-22,150,000
EBIT	$-58,978,000	$-43,445,000	$-54,976,000	$-27,366,000	$-33,962,000	$-38,784,000	$-6,403,000	$-16,665,000	$-26,171,000	$-24,618,000	$-22,066,000	$-21,367,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about JBIO

News

Jade Biosciences to Participate in Upcoming Conferences

Jade Biosciences, a clinical-stage biotechnology company, announced its participation in four upcoming healthcare innovation and biopharma conferences in November 2026. Management will host one-on-one investor meetings...

GlobeNewswire•Nov 3, 2026 7:11 AM ET11/3/26•Somewhat-Bullish

BTIG Maintains Jade Biosciences(JBIO.US) With Buy Rating, Maintains Target Price $77

BTIG has reiterated its Buy rating for Jade Biosciences (JBIO.US) and maintained its target price at $77. This indicates continued confidence in the company's performance and future outlook from the investment firm.

Moomoo•Oct 27, 2026 9:40 AM ET10/27/26•Bullish

BTIG reiterates Buy rating on Jade Biosciences, $77 price target

BTIG has reiterated a Buy rating on Jade Biosciences (JBIO) with a $77 price target, implying a 431.0% upside. The positive outlook is driven by the strong competitive positioning of JADE101...

TradingView•Oct 27, 2026 5:41 AM ET10/27/26•Bullish

Jade Biosciences, Inc. Estimates – NASDAQ:JBIO

This article provides an overview of Jade Biosciences, Inc. (NASDAQ: JBIO) financials and estimates available on TradingView. It directs users to explore reported financial data and analyst estimates across income...

TradingView•Oct 24, 2026 6:11 AM ET10/24/26•Neutral

Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026

Jade Biosciences announced that it will present three posters related to its JADE101 development program for IgA nephropathy (IgAN) at ASN Kidney Week 2026. The presentations will cover the scientific foundation...

Yahoo Finance Australia•Oct 21, 2026 4:40 PM ET10/21/26•Bullish

JBIO Valuation and Fair Value

P/B: 2.1x

See GNG's fair value

JBIO Profitability: Margins, ROIC and FCF

Operating margin: 0.0%
Net margin: 0.0%
ROE: -89.2%

JBIO Competitors

Company	Ticker
HealthStream Inc	HSTM
Corvus Pharmaceuticals Inc	CRVS
Immatics NV	IMTX
Theravance Biopharma Inc	TBPH
Syndax Pharmaceuticals Inc	SNDX
Pharming Group NV	PHAR
Savara Inc	SVRA
Oric Pharmaceuticals Inc	ORIC

Sector: Healthcare

JBIO Analyst Ratings

Consensus: Buy
Analysts: 10
Strong Buy: 0
Buy: 10
Hold: 0
Sell: 0
Strong Sell: 0

JBIO Bull Case vs Bear Case

Bull case

100.0% of JBIO's analyst ratings are Buy or Strong Buy.

Bear case

JBIO beat EPS estimates in 12.5% of its last 8 reported quarters.

JBIO Earnings: Beat Rate and Next Report

Beat rate: 1 of 8 quarters (12.5%)
Average surprise: -1104.1%
EPS estimate (fiscal period ending Sep 30, 2026): $-0.79
Estimate revisions (30 days, fiscal period ending Sep 30, 2026): 0 up, 1 down

JBIO Dividend

Forward yield: 0.0%

JBIO Earnings Date

JBIO reports Nov 11, 2026, after the close. The date is estimated.

JBIO ETF Holders

GNG tracks 11 ETFs that hold JBIO. The largest weights:

abrdn Healthcare Investors (HQH), 0.73% of the fund
State Street SPDR S&P Biotech ETF (XBI), 0.24% of the fund
Fidelity Growth Company Fund (FDGRX), 0.02% of the fund
iShares Russell 2000 ETF (IWM), 0.01% of the fund
Vanguard Health Care Index Fund ETF Shares (VHT), 0.01% of the fund

Open the ETF Stock Exposure tool for JBIO

Frequently Asked Questions About JBIO

When does JBIO report earnings?

Jade Biosciences, Inc. (JBIO) is expected to report earnings on Nov 11, 2026.

Does JBIO pay dividends?

Jade Biosciences, Inc. (JBIO) has a dividend payment track record. See the JBIO dividend history page for its current payment status, TTM yield, and recorded payments.

What is JBIO's market cap?

Jade Biosciences, Inc. (JBIO) has a market capitalization of $896.72M with a current stock price of $15.07.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In